Financial Advocates Investment Management’s Virtus Biotech ETF BBP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
– Sell
-8,455
Closed -$368K – 695
2022
Q1
$368K Sell
8,455
-120
-1% -$5.16K 0.02% 520
2021
Q4
$419K Sell
8,575
-1,200
-12% -$59.6K 0.03% 533
2021
Q3
$498K Hold
9,775
– – 0.03% 476
2021
Q2
$522K Sell
9,775
-620
-6% -$32.7K 0.03% 472
2021
Q1
$544K Sell
10,395
-1,000
-9% -$55.8K 0.04% 462
2020
Q4
$606K Sell
11,395
-250
-2% -$12.8K 0.04% 406
2020
Q3
$555K Hold
11,645
– – 0.05% 356
2020
Q2
$552K Hold
11,645
– – 0.05% 341
2020
Q1
$436K Hold
11,645
– – 0.06% 297
2019
Q4
$507K Sell
11,645
-1,200
-9% -$48.2K 0.05% 309
2019
Q3
$461K Hold
12,845
– – 0.05% 304
2019
Q2
$527K Sell
12,845
-1,000
-7% -$41.2K 0.06% 284
2019
Q1
$620K Hold
13,845
– – 0.08% 236
2018
Q4
$483K Buy
13,845
+750
+6% +$28.5K 0.07% 251
2018
Q3
$595K Sell
13,095
-260
-2% -$11.6K 0.07% 259
2018
Q2
$587K Sell
13,355
-550
-4% -$23.3K 0.07% 247
2018
Q1
$574K Hold
13,905
– – 0.07% 236
2017
Q4
$564K Buy
+13,905
New +$555K 0.08% 239

Other funds holding BBP

Financial Advocates Investment Management's BBP Position: Q2 2022 in Review

Financial Advocates Investment Management sold out of Virtus Biotech ETF (BBP) in Q2 2022, closing a stake of 8,455 shares — an estimated $368K sold.

Financial Advocates Investment Management first reported a position in BBP in Q4 2017 and held it in 18 quarters. The position peaked at $620K in Q1 2019. 11 funds tracked by Wall St. Rank hold BBP as of Q2 2022.

  • Financial Advocates Investment Management reported no remaining Virtus Biotech ETF position as of Q2 2022 after selling out during the quarter.
  • Financial Advocates Investment Management sold 8,455 Virtus Biotech ETF shares in Q2 2022, an estimated $368K.
  • Financial Advocates Investment Management first reported a position in Virtus Biotech ETF in Q4 2017 and held it in 18 quarters.
  • Financial Advocates Investment Management's Virtus Biotech ETF position peaked at $620K in Q1 2019.
  • 11 funds tracked by Wall St. Rank held Virtus Biotech ETF as of Q2 2022.

Based on Financial Advocates Investment Management's 13F filing for Q2 2022, filed 12 Aug 2022.